BPC157 10mg

BPC-157 (Body Protection Compound 157) 10mg is a synthetic pentadecapeptide designed for research and laboratory use. Derived from a partial sequence of the gastric cytoprotective protein BPC, BPC-157 has been investigated in preclinical models for its role in gastrointestinal mucosal protection, tendon and ligament healing, angiogenesis, and cytoprotection across multiple tissue types. Each vial is manufactured to pharmaceutical-grade purity standards to ensure consistency and reliability in research settings. Ideal for qualified researchers and institutions studying gut integrity, tissue repair, and NO-system modulation. Store in a cool, dry place away from direct light. For research purposes only. Not intended for human or veterinary use.

Specifications: Active Ingredient: BPC-157 (Body Protection Compound 157) Concentration: 10mg per vial Peptide Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Ala Molecular Formula: C₆₂H₉₈N₁₆O₂₂ Molecular Weight: ~1,419.55 Da (free base) Classification: Synthetic pentadecapeptide (15 amino acids) Purity: ≥98% (HPLC) Form: Lyophilised powder Appearance: White to off-white powder Storage: 2–8°C (refrigerated) Shelf Life: 24 months from manufacture date Reconstitution: Sterile bacteriostatic water or saline Intended Use: Laboratory and research applications only

Storage Before Reconstitution: Store in original sealed vial at 2–8°C away from direct sunlight and moisture. Stable for 24 months when stored properly. Storage After Reconstitution: Store reconstituted solution at 2–8°C and use within 7–14 days. For extended storage, freeze at −20°C for up to 3 months; thaw at 2–8°C before use. Avoid repeated freeze-thaw cycles. Use sterile technique throughout. For research use only. Not intended for human or veterinary use.

Research References

The following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.

1. BPC-157: Gastric Cytoprotection and Origin
   Sikiric P, et al. (1993). The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. European Journal of Pharmacology, 332(1), 23–33. https://doi.org/10.1016/S0014-2999(97)01033-5
   One of the foundational studies characterising BPC-157 as a gastric cytoprotective pentadecapeptide, demonstrating its interaction with the NO-system in gastric mucosal protection and establishing the mechanistic basis for its cytoprotective research applications.
2. BPC-157 and Tendon-to-Bone Healing
   Staresinic M, et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 21(6), 976–983. https://doi.org/10.1016/S0736-0266(03)00110-4
   Demonstrates accelerated Achilles tendon healing and in vitro tendocyte proliferation following BPC-157 administration in rat models, establishing its cytoprotective and musculoskeletal tissue-repair profile in preclinical research.
3. BPC-157 and Gut Barrier Integrity
   Sikiric P, et al. (2016). Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (IBD): new insight. Current Pharmaceutical Design, 22(36), 5462–5475. https://doi.org/10.2174/1381612822666160804095040
   Reviews BPC-157’s protective effects on intestinal mucosal integrity in inflammatory bowel disease models, covering its modulation of growth factor expression, tight junction proteins, and NO-system activity — providing key context for gastrointestinal research applications.
4. BPC-157 and Angiogenesis
   Sikiric P, et al. (2010). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts and accelerated tendon healing. Journal of Physiology and Pharmacology, 61(6), 677–685. (See also: Chang CH, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774–780.) https://doi.org/10.1152/japplphysiol.00945.2010
   Demonstrates BPC-157’s promotion of tendon outgrowth, fibroblast survival, and cell migration via VEGFR2 and FAK-paxillin pathway activation, establishing its pro-angiogenic and pro-migratory mechanisms relevant to vascular and tissue repair research.
5. BPC-157 Systemic Cytoprotection: Comprehensive Review
   Sikiric P, et al. (2018). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 24(18), 1990–2001. https://doi.org/10.2174/1381612824666180608101119
   Comprehensive review of BPC-157’s cytoprotective mechanisms across gastrointestinal, vascular, musculoskeletal, and neurological tissue models, covering NO-system modulation, growth factor upregulation, and anti-inflammatory signalling — the most complete single reference for BPC-157 research scope.

All references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.